Anthony Rodgers
Professor / Professorial Fellow at The George Institute for Global Health, affiliated with UNSW Sydney
Data updated
Research Footprint
Anthony Rodgers appears in 6 tracked papers (2018–2025), most studied alongside Ketamine and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Ketamine for the treatment of major depression: a systematic review and meta-analysis (154 citations).
Frequent co-authors: Colleen Loo, Paul Glue and Donel Martin.
Background & Research
Anthony Rodgers is a health researcher and professor at The George Institute for Global Health, affiliated with UNSW Sydney. He has co-authored multiple ketamine-for-depression studies, including the KADS trial, as well as work on the economic and policy barriers to making ketamine treatment accessible. His broader career spans global health and evidence-based medicine, with a strong focus on translating research into practice.
Key Impact
He is a key non-psychiatrist collaborator on major ketamine depression trials and related health-economics work that helped advance evidence and access discussions for off-patent ketamine treatments.
Collaboration Network
5 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Anthony Rodgers is associated with.
The George Institute
nonprofitAn independent international research institute focused on preventing and treating the world's leading causes of death and disability. With centers in Australia, China, India, and the UK, the George Institute for Global Health conducts large-scale clinical trials and population health studies addressing cardiovascular disease, stroke, kidney disease, and mental health.
View stakeholder →University of Sydney
academicThe Brain and Mind Centre is advancing psychedelic science with a multidisciplinary focus on developing innovative treatments using AI and preparing for human clinical trials to treat severe mental illness.
View stakeholder →